“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas

Author:

Jain Rajan1,Johnson Derek R2,Patel Sohil H3,Castillo Mauricio4,Smits Marion5,van den Bent Martin J6,Chi Andrew S7,Cahill Daniel P8

Affiliation:

1. Departments of Radiology and Neurosurgery, New York University Langone Health, New York, New York, USA

2. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA

3. Department of Radiology, University of Virginia Health, Charlottesville, Virginia, USA

4. Department of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA

5. Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands

6. Department of Neurology, Erasmus MC, Rotterdam, Netherlands

7. Mirati Therapeutics, San Diego, California, USA

8. Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA

Abstract

Abstract AbstractThe T2-FLAIR (fluid attenuated inversion recovery) mismatch sign is an easily detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate dehydrogenase (IDH)–mutant 1p/19q non-codeleted gliomas. Multiple independent studies show that the T2-FLAIR mismatch sign has near-perfect specificity, but low sensitivity for diagnosing IDH-mutant astrocytomas. Thus, the T2-FLAIR mismatch sign represents a non-invasive radiogenomic diagnostic finding with potential clinical impact. Recently, false positive cases have been reported, many related to variable application of the sign’s imaging criteria and differences in image acquisition, as well as to differences in the included patient populations. Here we summarize the imaging criteria for the T2-FLAIR mismatch sign, review similarities and differences between the multiple validation studies, outline strategies to optimize its clinical use, and discuss potential opportunities to refine imaging criteria in order to maximize its impact in glioma diagnostics.

Funder

Radiological Society of North America research scholar

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Reference35 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3